A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

NCT04039919 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class

Stopped Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures

Conditions

Interventions

Sponsor

UCB Biopharma S.P.R.L.